Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP707 Delivered Systemically for the Treatment of Solid Tumors
HONG KONG, Feb. 9, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced the start of a Phase I clinical trial for evaluation of the safety, tolerability and anti-tumor activity of the Company's siRNA (small interfering RNA) drug candidate, STP707 with intravenous (IV)...
Hummingbird Bioscience Publishes Preclinical Data Demonstrating Therapeutic Potential of HMBD-002 in VISTA-expressing Cancers
HOUSTON and SINGAPORE, Feb. 9, 2022 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets in cancer and autoimmune disease, today announced the publication of preclinical data for HMBD-002, a novel anti-VISTA antibody therapeutic, in the Journal for ImmunoTherapy of Cancer, a peer-reviewed journal of the Society for Immunotherapy of Cancer....
Glenmark and SaNOtize announce positive Results from Phase 3 Clinical Trial of NONS (FabiSpray®) in Non-Hospitalized Adult Indian Patients with COVID-19
Phase 3 trial in India met the key endpoints and demonstrated reduction of viral load of 94% in 24 hours and 99% in 48 hours. NONS was safe and well tolerated in COVID-19 patients. Glenmark received manufacturing and marketing approval from India's drug regulator for Nitric Oxide Nasal Spray (NONS) as...
COLOPLAST SINGAPORE LAUNCHES SENSURA MIO(R), A PRODUCT MADE WITH THE LATEST TECHNOLOGY FOR OSTOMY AND STOMA CARE
SenSura® Mio features BodyFit technology, an elastic adhesive technology fit for all peristomal body profiles. SINGAPORE, Feb. 9, 2022 /PRNewswire/ -- Coloplast, one of the world's leading manufacturers of stoma care products launches its latest product innovation, the SenSura® Mio in Singapore this year. Singapore is the first country in Southeast Asia that launches SenSura® Mio and...
CStone announced new drug approval of China’s first IDH1 inhibitor TIBSOVO® (ivosidenib tablets) as a new precision therapy for patients with acute myeloid leukemia
TIBSOVO®, a first-in-class drug, is approved for adult patients with relapsed/refractory acute myeloid leukemia (R/R AML) who have a susceptible IDH1 mutation Clinical study data showed that TIBSOVO® had robust clinical efficacy and a well-tolerated and manageable safety profile in Chinese adult patients with R/R AML who have a susceptible IDH1 mutation TIBSOVO® became CStone's fourth...
Bugworks Research Inc. secures US$18M Series B1 Funding from Reputed Global Investor Syndicate (The EU, UK, Japan, South Africa & India), led by Lightrock India
This Funding will advance highly differentiated assets in the dual areas of Antimicrobial Resistance (AMR) and Immuno-Oncology (IO) BANGALORE, India, SARATOGA, Calif. and ADELAIDE, Australia, Feb. 9, 2022 /PRNewswire/ -- Bugworks Research, a clinical stage multi-indication therapeutics company, today announced the financing of US$18M Series B1. This round will support the clinical...
Bactiguard presents focused growth strategy and sets new long-term financial targets
STOCKHOLM, Feb. 9, 2022 /PRNewswire/ -- Bactiguard presents new long-term financial targets in connection with the year-end report for 2021. The new financial targets relate to growth and profitability, with annual revenues of at least 1 billion SEK and annual EBITDA of at least 400 million SEK in 2026. "With Bactiguard's unique technology for infection prevention, scalable business model,...
First Proton Therapy Treatment Delivered in Southeast Asia at Her Royal Highness Princess Maha Chakri Sirindhorn Proton Center, Thailand
BANGKOK, Feb. 9, 2022 /PRNewswire/ -- Varian, a Siemens Healthineers company, today announced that Her Royal Highness Princess Maha Chakri Sirindhorn Proton Center has begun treating patients with its new Varian ProBeam® proton therapy system, the first of its kind in Thailand and Southeast Asia. Clinicians used the new system to target a complicated abdominal cancer using carefully shaped high-definition...
Bactiguard and Zimmer Biomet expand global license partnership
STOCKHOLM, Feb. 9, 2022 /PRNewswire/ -- Bactiguard and Zimmer Biomet have today agreed to expand the global license partnership, that was initiated in 2019, to cover multiple product segments. The extended exclusive license agreement covers implants for joint reconstruction (hips and knees), sports medicine, craniomaxillofacial and thoracic applications. It includes license and development fees of USD 1.5 million...
Cambrex Recognized with 2022 CMO Leadership Awards for the 8th Consecutive Year
EAST RUTHERFORD, N.J., Feb. 8, 2022 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), announced today that it has been recognized by the annual CMO (Contract Manufacturing Organization) Leadership Awards in the categories of Quality and Service. This marks the eighth consecutive year Cambrex has been acknowledged with...
